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Abstract
Anti-HIV microbicides are being investigated in clinical trials and understanding how promising strategies work, coincident
with demonstrating efficacy in vivo, is central to advancing new generation microbicides. We evaluated CarraguardH and a
new generation Carraguard-based formulation containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-
150 (PC-817). Since dendritic cells (DCs) are believed to be important in HIV transmission, the formulations were tested for
the ability to limit DC-driven infection in vitro versus vaginal infection of macaques with RT-SHIV (SIVmac239 bearing HIV
reverse transcriptase). Carraguard showed limited activity against cell-free and mature DC-driven RT-SHIV infections and,
surprisingly, low doses of Carraguard enhanced infection. However, nanomolar amounts of MIV-150 overcame
enhancement and blocked DC-transmitted infection. In contrast, Carraguard impeded infection of immature DCs
coincident with DC maturation. Despite this variable activity in vitro, Carraguard and PC-817 prevented vaginal transmission
of RT-SHIV when applied 30 min prior to challenge. PC-817 appeared no more effective than Carraguard in vivo, due to the
limited activity of a single dose of MIV-150 and the dominant barrier effect of Carraguard. However, 3 doses of MIV-150 in
placebo gel at and around challenge limited vaginal infection, demonstrating the potential activity of a topically applied
NNRTI. These data demonstrate discordant observations when comparing in vitro and in vivo efficacy of Carraguard-based
microbicides, highlighting the difficulties in testing putative anti-viral strategies in vitro to predict in vivo activity. This work
also underscores the potential of Carraguard-based formulations for the delivery of anti-viral drugs to prevent vaginal HIV
infection.
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Introduction
Education and condom use can help limit HIV-1 transmission
[1–3], but as currently applied do not represent definitive solutions.
Thus, additional strategies are required to stem the spread of
infection [4]. Vaccine and microbicide strategies tested to date have
not been successful [5–8]. In light of recent setbacks in vaccine
research [9], there is an even greater need to identify alternative
approaches that reduce the risk of acquiring HIV-1 infection.
Microbicides, operationally defined as substances intended to
reduce or prevent transmission of HIV and/or other sexually
transmitted infections (STIs) when applied topically to genital
mucosal surfaces (www.microbicide.org), represent one such option.
While the efficacy of a topically applied microbicide is likely to
depend on the timely and correct application of the product relative
to potential exposure, the availability of such products still
represents an important strategy that could help stem the spread
of HIV-1. Experience with such products may also usefully inform
the development of alternative, coitus independent strategies.
Development of current and future microbicides must take into
account our cumulative knowledge of HIV transmission. The early
events leading to HIV passage across the genital mucosa likely
involves HIV capture by a wide variety of molecules on the surface
of epithelial cells and/or leukocytes followed by infection of
permissive target cells within the tissues. In vitro virus transmission
models have shown that dendritic cells (DCs) can capture virus
and efficiently transmit these virions to CD4 T cells across
infectious synapses between DCs and T cells [10–14]. CCR5-using
HIV (R5 HIV) can productively infect immature DCs, like those
located at the body surfaces, with the newly produced viruses
being readily transferred to T cells [15]. In addition, both
immature and mature DCs can effectively internalize viruses and
transfer these virions to T cells, in the absence of productive
infection of the DCs [10–12,14,16–18]. It is likely that immediate
capture of virus by mucosa-associated DCs then transmits the virus
to CD4 T cells, where robust virus replication occurs [10,15,19],
consistent with other evidence for a more dominant role for CD4
T cells in the subsequent amplification of virus [20–22]. Thus, we
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infection in DCs or DC-T cell co-cultures may provide a more
rigorous and relevant in vitro evaluation of the capacity of potential
microbicide formulations.
Microbicide strategies currently being explored include broad-
acting formulations that block HIV attachment (e.g., Carraguard,
Pro 2000, BufferGel), specific small molecule inhibitors that target
viral or cellular molecules critical for virus attachment, entry, or
fusion (e.g., CCR5 inhibitors, fusion inhibitors like T-1249, anti-
envelope Abs), and anti-viral drugs (e.g., PMPA, TMC-120, UC-
781, MIV-150) [23]. The appeal of the broad-acting compounds is
that they should prevent HIV interactions with any cell type
(independent of the molecules involved) while also potentially
havingactivityagainst otherSTIs.Carraguard,isarepresentative of
this group, and has been shown to have potent activity against X4
HIV isolates with more limited activity against R5 HIV isolates in
vitro[24–30],aswellashaving activityagainst otherSTIs[31–36].A
recently completed Phase III efficacy trial testing the ability of
Carraguard to prevent HIV infection in women revealed that
Carraguard is safe and while the frequency of HIV infection was
lower in the Carraguard arm (134 vs 151 seroconversions in the
placebo group), this was not a statistically significant difference [8].
In addition to safety, the inherent rheological properties and
stability profile of Carraguard renders it a promising formulation
vehicle,which may also have some anti-viral activity, to which other
anti-viral agents could be added to provide a more effective
microbicide.
The aim of this study was to evaluate the capacity of a
microbicide (PC-817) comprised of Carraguard and the non-
nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 to
inhibit DC-driven infection in vitro and prevent vaginal immuno-
deficiency virus infection in macaques. MIV-150 (developed by
Medivir, AB, Sweden, and licensed to the Population Council) is a
tight-binding NNRTI with a rapid association and slow dissoci-
ation rate, which has activity against a variety of HIV-1 isolates, as
well as HIV-2 [37]. MIV-150 also has virucidal activity against
cell-free HIV and its anti-viral activity is not affected by seminal
fluid [37]. We provide the first evidence of the additive effects of
Carraguard and MIV-150 against DC-mediated infections in vitro
and demonstrate the efficacy of Carraguard-based gels and
topically applied MIV-150 in vivo.
Materials and Methods
Cell culture and reagents: SUPT1/CCR5 CL.30 cells
(provided by J. Hoxie, University of Pennsylvania) and 1746CEM
cells (AIDS Research and Reagent Program, courtesy of Peter
Cresswell) were maintained in RPMI 1640 (Cellgro; Fisher
Scientific, Springfield, N.J.) with 10% (v/v) heat-inactivated fetal
calf serum (FCS, Cellgro). The TZM.bl cell line (AIDS Research
and Reagent Program, courtesy of Dr. John C. Kappes, Dr.
Xiaoyun Wu and Tranzyme Inc) was maintained in DMEM
(Cellgro) with 10% (v/v) heat-inactivated FCS. Peripheral blood
mononuclear cells (PBMCs) were isolated from HIV seronegative
leukocyte-enriched preparations purchased from the New York
Blood Center using Ficoll-Hypaque density gradient centrifugation
(Amersham Pharmacia Biotech, Uppsala, Sweden). Monocytes
were isolated using CD14 magnetic cell sorting (Miltenyi Biotec,
Auburn, CA), with washing and elution in cold 16 PBS
supplemented with 1% AB human serum (Cellgro) and 1 mM
EDTA (Sigma). Monocyte purity was verified in each experiment
by CD14 (MP9) and CD3 (Leu-4) staining (both Becton
Dickinson, San Jose, CA), with cut-off purities of 2% CD3 T
cells. Monocytes were subsequently cultured in RPMI 1640
(Cellgro) containing 10 mM HEPES (GIBCO-BRL, Life Tech-
nologies, Grand Island, NY), 2 mM L-glutamine (GIBCO-BRL),
50 mM 2-mercaptoethanol (Sigma, St. Louis, MO), penicillin
(100 U/ml)-streptomycin (100 mg/ml) (GIBCO-BRL), and 1%
heparinized human plasma (Innovative Research, Southfield, MI)
supplemented with 100 U/ml recombinant human interleukin-4
(IL-4) (R&D Systems, Minneapolis, MN) and 1000 U/ml
recombinant human granulocyte-macrophage colony-stimulating
factor (GM-CSF) (Biosource/Invitrogen, Carlsbad, CA). To
generate mature DCs, day 5-cultured immature DCs were
exposed to a maturation cocktail of IL-1b (10 ng/ml), IL-6
(1,000 U/ml), TNF-a (10 ng/ml) (all from R&D Systems,
Minneapolis, MI) and PGE2 (1 mg/ml) (Sigma) for 48 hours.
The phenotype of immature and mature DCs was routinely
monitored by two-color flow cytometry using FITC-conjugated
mouse Ab against HLA-DR (Becton Dickinson) combined with
the following panel of phycoerythrin (PE)-conjugated mouse anti-
human monoclonal Abs (MAbs): anti-CD25, -CD80, -CD86 (all
Becton Dickinson), and -CD83 (PN IM2218; Immunotech,
Marseille, France).
Microbicide preparations: Carraguard (Lot numbers
032805, 102505, 032906-A, 011005-B, and 010908) was prepared
as a 3% (w/v) stock as described [34]. PC-817 (Lot numbers
032805, 102705, 040306-B, 011005, and 032707-A) was prepared
adding a DMSO (Sigma) or ethanol solution of MIV-150 (Medivir
AB, Sweden) to Carraguard, to a final concentration of 500 mM.
2.5% (25 mg/ml) methylcellulose (MC; Lot numbers 032805,
110205, 033006-A, 011005-A, 032807, and 011008) (Fisher) was
used as a placebo vehicle control gel for the in vivo studies. To test
the in vivo activity of MIV-150 alone, MIV-150 was mixed with
25 mg/ml MC (Lot numbers 040306-A, 032707B, and 011908).
All gels were stored at room temperature. In vitro assays with MIV-
150 were set up using 10 mM MIV-150 stocks dissolved in
DMSO. 3% Carraguard stock solutions were diluted initially 1:10
(v/v) with 16 PBS using a positive displacement pipette
(Eppendorf, Hamburg, Germany).
Virus stocks and titering: HIVMN and HIVBal stocks were
sucrose gradient purified lots #P3764 and #P3953 (courtesy of the
AIDS and Cancer Virus Program, SAIC-Frederick, Inc., National
Cancer Institute, Frederick, MD). The RT-SHIV construct is a
hybridofSIVmac239bearingthereversetranscriptasegene derived
from HIV HXB2 [38,39]. RT-SHIV stocks for in vivo inoculations
were grown in PHA activated human PBMCs (kindly provided by
Disa Bo ¨ttiger, Medivir AB, Sweden). RT-SHIV stocks were titered
using the 1746CEM cell line and TCID50 was calculated according
to the Reed and Muench formula.
For in vitro assays, a purified and high titer stock of RT-SHIV
was generated as follows: 4 liters of viral supernatant were
produced in the 1746CEM cell line and harvested over a period
of 28 days. Viral supernatant was pre-cleared of cellular debris, by
centrifugation at 18006g for 30 min at 4uC using a benchtop
centrifuge (Eppendorf). Virus was then concentrated 100 fold,
using a Labscale tangential filter flow apparatus connected in
parallel with two Pellicon XL 50 Cassettes with 1000 kDa
molecular weight cut-off (Millipore, Billerica, MA). For 37 ml of
virus filter concentrate, virus pellets were generated by ultracen-
trifugation in a SW28 rotor (Beckman-Coulter, Fullerton, CA) at
100,000 g through a 1 ml 20% glycerol cushion and then virus
was resuspended in 400 ml of PBS and layered onto a 9 step 24%
to 56% sucrose gradient. Virus was subsequently ultracentrifuged
in a SW55Ti rotor (Beckman-Coulter) at 100,0006g for 3 hours
with acceleration and deceleration set at 5 and 9 respectively. For
sucrose gradients, peak viral fractions were harvested by analyzing
A280 using a spectrophotometer and were later confirmed to
Carraguard-Based Microbicides
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Harvested fractions were diluted 1 in 5 ml in 16 PBS and
subsequently pelleted at 100,0006g for 90 min in a SW55 rotor
(Beckman-Coulter). The pellets were resuspended overnight in
1 ml of PBS and stored at 280uC. The titer (2.49610
8 TCID50/
ml) was determined using 1746CEM cells as described above.
HIV/SIV infections and mature DC transfer assays:
TZM.bl cells (plated at 5610
3 cells/well in 96 well flat-bottomed
plates 16 hours earlier) or PBMCs activated for 48 hours with
5 mg/ml PHA (Sigma) (10
6 cells/ml in 200 ml in 96 well round-
bottomed plates) were treated with compounds for 30 min at 37uC
and then challenged with 300 TCID50 of HIVBal or HIVMN or
600 TCID50 of RT-SHIV. Activated PBMCs were recultured with
complete media supplemented with 10 U/ml of IL2(Roche). For
immature and mature DCs, 1.5610
5 cells (in 150 ml) were
pretreated with compounds and pulsed with either 3000 TCID50
of HIVBal, 4500 TCID50 of RT-SHIV or 3000 TCID50 of VSVg
pseudotyped, delta HIV envelope NL43 in 96 well V-bottomed
plates (Corning, NY). After 2 hours at 37uC, mature DCs were
washed 4 times in media and then 10
3 DCs were added to 5610
3
TZM.bl indicator cells or 5610
3 DCs were also added to equal
numbers of either SUPT1/CCR5 CL.30 cells (for HIVBal)o r
1746CEM cells (for RT-SHIV). Detection of virus transfer to
TZM.bl cells was by X-gal staining as described [15,40]. Detection
of transfer to SUPT1/CCR5 CL.30 cells was by Q-PCR for HIV
gag DNA and RT-SHIV transfer to 1746CEM cells was by Q-
PCR for SIV gag DNA, as a function of cell numbers by using Q-
PCR for albumin DNA [41,42]. Virus-pulsed immature DCs were
washed before being cultured in 96 well round-bottomed plates at
10
6 cells/ml in 200 ml of IL-4/GM-CSF media. Infection of
immature DCs was monitored using intracellular stain for HIV
gag p24 [43]. The percent inhibition of infection was calculated
using the following equation:
% Inhibition~ 1{ sample value=control value ðÞ ðÞ |100
Microbicide application and in vivo challenge: Adult
female Chinese rhesus macaques (Macaca mulatta) were housed at
the Tulane National Primate Research Center (TNPRC; Coving-
ton, LA). All studies were approved by the Animal Care and Use
Committee of the TNPRC. Animal care procedures were in
compliance with the regulations detailed in the Animal Welfare
Act [44] and in the ‘‘Guide for the Care and Use of Laboratory
Animals’’ [45]. All naı ¨ve animals tested negative for simian type D
retroviruses, simian T cell leukemia virus-1, and SIV prior to use.
Prior to virus challenge, animals received a single 30 mg i.m.
injection of Depo-Provera. 35 days later, the macaques were
sedated and 3 ml of compound were introduced atraumatically
into the vaginal vault using a pliable French catheter. 1 ml of virus
was applied 30 min later. At appropriate time points, pre and post
viral challenge, animals were anesthetized with ketamine-HCl
(10 mg/kg) prior to EDTA blood samples being taken (no more
than 10 ml/kg/month/animal).
Anti-CD8 depletion: Monkeys were treated with the mouse-
human chimeric anti-CD8 mAb cM-T807 (NIH Nonhuman
Primate Reagent Resource-Beth Israel Deaconess Medical Center,
Boston, MA), receiving 10 mg/ml s.c. at day 0, followed by 5 mg/
kg i.v. on days 3, 7, and 10 [46]. To verify CD8 cell depletion,
whole blood was stained according to the manufacturer’s
guidelines for phycoerythrin (PE)-conjugated anti-CD8 (clone
DK25; BD Pharmingen), fluorescein isothiocyanate (FITC)-
conjugated anti-CD4 (clone L200; Dako), peridinin-chlorophyll-
Cychrome (PerCP-Cy5.5)-conjugated anti-CD3 (clone SP34; BD
Pharmingen).
Plasma viral load: Plasma was collected from whole EDTA
blood after bench top centrifugation (Eppendorf) at 8006g for
10 min. Contaminating platelets were removed by a second
centrifugation at 8006g for 10 min. Plasma was then stored in
1 ml aliquots at 280uC until plasma viral load RNA detection.
Measurement of plasma viral loads by quantitative RT-PCR was
performed as previously described [47,48]. We defined animals
that were ‘‘infected’’ as those which recorded greater than 1000
RNA copies/ml in $2 samples post infection. Animals defined as
‘‘uninfected’’ had undectectable viral RNA for the duration of the
viral challenge study (20 weeks) or ,1000 RNA copies per ml at
,2 time points post challenge.
ELISPOT assay: ELISPOT assays were performed as
previously described [47,49] using 300 ng p27/ml of AT-2
inactivated SIVmneE11S [50] (Lot# p3926, courtesy of the
AIDS and Cancer Virus Program, SAIC-Frederick) as the SIV
antigen (vs the no virus microvesicle controls). SIV-specific
responses were determined by subtracting the responses detected
in control cultures from those induced by AT-2 SIV. In each
experiment, PBMCs were also cultured with 5 mg/ml Concanav-
alin A (Sigma) to control for PBMC functionality and assay
integrity. Spots were counted using an AID ELISPOT reader (Cell
Technology, Columbia, MD) with once optimized settings through
all experiments and the mean (6SEM) numbers of spot forming
cells (SFCs) from triplicate or duplicate cultures per animal were
enumerated.
SIV specific antibody response: Plasma samples obtained
were monitored for the presence of SIV envelope Abs by using an
established ELISA protocol [51].
Whole blood CD8/CD4 T-cell counts: Absolute CD4 and
CD8 cell counts were monitored by TruCount (BDBiosciences,
Palo Alto, CA) staining of whole blood at the indicated time points.
Statistical analyses used in this study: Unless otherwise
stated, data was tested for normal distribution using Origin
software (Shapiro-Wilk test) (Originlab corporation, Northhamp-
ton, MA). For statistical comparisons, 2-tailed and paired t tests
were used for the in vitro analyses. Fisher’s Exact was calculated for
in vivo analyses [52], with the aid of software published online at
http://www.langsrud.com/fisher.htm. Standard p values ,0.05
were taken as statistically significant.
Results
Carraguard can inhibit or enhance infection in vitro
In order to evaluate a combined MIV-150/Carraguard
formulation in macaques, it was necessary to use a virus isolate
that was sensitive to the drug while also infectious in vivo.
Consistent with the lack of activity of other NNRTIs against the
reverse transcriptase of SIV, there was little or no in vitro activity of
MIV-150 against wild type SIVmac239, SHIV-162P3, or
SIVmac316 (data not shown). Thus, a chimeric RT-SHIV isolate
expressing HIV-1 reverse transcriptase was chosen, which has
been shown to be infectious in vivo and sensitive to MIV-150 [38].
The first aim was to compare the ability of Carraguard to block
RT-SHIV versus HIV infection in standard in vitro assay systems.
Using TZM.bl cells, HIVBal was inhibited by Carraguard in dose
dependent manner over the viral titration, while Carraguard was
ineffective against RT-SHIV at or below 6000 TCID50/ml
(p.0.05, Fig. 1A). Surprisingly, there was a statistically significant
increase in RT-SHIV infection (300–3000 TCID50/ml) in the
presence of very low doses (,2 mg/ml) of Carraguard (p,0.05). At
higher virus inocula there were reductions in infections and this
Carraguard-Based Microbicides
PLoS ONE | www.plosone.org 3 September 2008 | Volume 3 | Issue 9 | e3162correlated with loss of the cellular integrity due to extensive viral
cytopathic effect (evident upon microscopic examination). Titrated
amounts of Carraguard were tested against sub-saturating doses of
RT-SHIV vs HIVBal and HIVMN (Fig. 1B). As expected, the X4
HIVMN strain was potently inhibited in a dose-dependent manner
(IC50=0.030 mg/ml60.007; n=3). In contrast, the HIVBal
inhibition curve was non sigmoidal and Carraguard was two
orders of magnitude less potent against this isolate
(IC50=4.17 mg/ml62.35; n=3). RT-SHIV was not only three
orders of magnitude less sensitive to Carraguard (IC50=27.39 mg/
ml66.77; n=3) than HIVMN, but at amounts of ,10 mg/ml of
Carraguard there was evidence of enhancement (although this was
not statistically significant, p.0.05).
To evaluate whether this enhancement was restricted to the
TZM.bl cell line, activated PBMCs were treated with varying
doses of Carraguard before being challenged with HIVBal or RT-
SHIV. In contrast to the TZM.bl cell line, there was significant
enhancement of infection with HIVBal below 10 mg/ml of
Carraguard (p,0.02 for 2 mg/ml Carraguard vs the media
control) and the enhancement of RT-SHIV was even more
pronounced with significant levels of enhancement between 2 and
20 mg/ml (p,0.05 over this range) (Fig. 1C).
Carraguard enhances DC-mediated amplification of virus
in T cells
Since DCs are so effective at capturing HIV [53,54], it is likely
that DC-driven dissemination and amplification of virus in CD4 T
cells occurs at the mucosa in vivo [10,42]. We set out to establish a
robust, reproducible assay with which we could monitor putative
microbicide formulations for their ability to prevent such DC-
mediated virus spread. In every experiment we utilized mature DCs
andcomparedCD4T celllinestotheTZM.blcellsastherecipients,
to control for donor specific-differences (in the recipient cells) and
the data shown are representative of both co-culture methods.
Mature DCs readily transmitted both HIVBaland RT-SHIV to the
recipient cells. Significant increases in the levels of infection were
observed in the presence of 10 mg/mlofCarraguard(Fig.2A;p,0.05
for 2610
3–5610
4 TCID50/ml of HIVBal and for 3610
3–1.5610
4
TCID50/ml of RT-SHIV). Using sub-saturating concentrations of
virus, significant levels of enhancement were observed over
Carraguard concentrations ranging from 2 to 50 mg/ml, with peak
levelsofenhancementoccurringat6 mg/mlforbothviruses(Fig.2B).
The peak enhancement of RT-SHIV infection was significantly
higher than that observed for HIVBal (p,0.04). To more closely
dissect the mechanism of this enhancement, mature DCs were loaded
with virus in the presence (Pre) or absence of Carraguard and then
also included Carraguard in the DC/recipient co-cultures (Post; for
those DCs not pre-treated with Carraguard). Enhancement of
infection by the lower Carraguard doses was observed when it was
present either during the virus pulse of the DCs (Pre) or during the
DC/recipient cultures (Post) (Fig. 2C). The peak level of enhance-
ment of RT-SHIV infection was not significantly different in either
condition (p.0.05), although the peak enhancement of HIVBal
infection was significantly greater for the pre-treated condition
Figure 1. Carraguard can inhibit or enhance cell-free infection. (A) TZM.bl cells were exposed to 0–10 mg/ml of Carraguard, before graded
doses of HIVBal or RT-SHIV were added. 24 h later, the media was replaced and cells were cultured for 4 d. The numbers of b-gal expressing SFCs per
well are shown (mean6SD, triplicate cultures). (B) Titrated amounts of Carraguard were tested against of HIVMN (MN, up triangles), HIVBal (Bal) (down
triangles), or RT-SHIV (circles) in the TZM.bl cell line as in (A). The data are shown as the percent inhibition (mean6SD, triplicate cultures) of infection
in the test conditions relative to the no Carraguard control. Negative % inhibition values represent enhancement, with no inhibitor effect at 0%. (C)
Titrated amounts of Carraguard were added to PHA activated PBMCs before the cells were cultured with Bal or RT-SHIV for 5 d. Infection was
measured by Q-PCR. Data are shown for triplicate cultures (mean6SD). Data in (A–C) are representative of 3 independent experiments with different
donors in each case.
doi:10.1371/journal.pone.0003162.g001
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recipient cells would enhance virus transmission and subsequent
replication [55], the formation of conjugates was monitored in the
presence of the low ‘‘enhancing’’ dose of Carraguard. However, the
presence of 6 mg/ml of Carraguard, did not affect the percentages of
mature DC-CD4 T cell conjugates (14.73%62.12 vs 13.93%62.18
for cells cultured in medium vs Carraguard for 24 h).
Carraguard inhibits infection of immature DCs coincident
with DC maturation
Given the unexpected result that low doses of Carraguard
increased virus replication facilitated by mature DCs, the impact
of Carraguard on infection of immature DCs was investigated.
Monitoring immature DC infection in contrast to mature DC-
mediated infection is important at several levels. Firstly, immature
DCs in healthy non-inflamed mucosa are hypothesized to be one
of the first leukocytes contacting HIV [14,23,56]. Secondly, the
dynamic nature of DC interactions with CD4 T cells provides
immature DCs the capacity to be highly efficient at viral transfer at
low numbers over long periods of time [10,19,57,58].
Carraguard potently inhibited HIVBal infection of immature DCs
in a dose-dependent manner (Fig. 3A, IC50=1.61mg/ml60.21,
n=4), as detected by flow cytometry analysis of HIV p24 expression
(since residual Carraguard interferes with the PCR assay). Upon
e x a m i n i n gt h ec u l t u r e si tw a sa p p a r e n tt h a tt h ei m m a t u r eD C sw e r e
reacting to Carraguard; the cells rapidly adhered to the plates (within
2 hours) and then cell clustering (as seen with maturing DCs) was
more apparent over time. In addition, cytokine profiles of immature
DCstreated withincreasingdosesofCarraguard revealedproduction
of TNF-a at doses greater than 50 mg/ml (data not shown). Flow
cytometric analysis of Carraguard-treated DCs revealed a dose-
dependent up-regulation of the DC maturation markers CD83 and
CD86 (Fig. 3B). Knowing that DC maturation significantly impacts
the levels of HIV replication, even when the stimulus is added after
virus has been captured by the DCs [59,60], we wanted to ascertain
whether the Carraguard effect was acting at a later stage of the virus
life cycle (and not necessarily at the level of virus capture or spread
between cells). To do so, immature DCs were infected with VSVg
envelope pseudotyped HIV NL43 delta envelope (VSV-HIV Denv,
which will not spread between cells), 16 hours later the cells were
washed, and graded doses of Carraguard were added. As with HIVBal
infection, Carraguardblocked VSV-HIV Denv infection of immature
DCs (Fig. 3A; IC50=1.61 mg/ml60.21, n=4 for both viruses).
Because Carraguard was added 16 hours after the addition of virus
and VSV-HIV Denv would not spread between cells, the inhibitory
capacity of Carraguard could not be associated with initial
attachment and fusion.
To further correlate the maturation of immature DCs with
inhibition of viral production, the appearance of the HIV p24
antigen was plotted against the mean fluorescence intensity (MFI)
of the maturation marker CD83 (Fig. 3C). The appearance of
CD83 negatively correlated with the expression of intracellular
HIV p24 by DCs infected with either HIVBal or VSV-HIV Denv
(r=20.86, p,0.03 and r=20.91, p,0.02 for HIVBal and VSV-
HIV Denv, respectively; n=4 for both viruses). Thus, the ability of
the compound to inhibit viral replication in this setting appeared
to be due to its ability to induce DC maturation.
The NNRTI MIV-150 overcomes Carraguard-mediated
enhancement of infection
Preliminary in vitro studies examining the NNRTI MIV-150
(50 mM) and Carraguard in a combination formulation designated
Figure 2. Carraguard augments mature DC-mediated amplification of infection. (A) Mature moDCs were pre-incubated with 0, 10, or
200 mg/ml Carraguard and challenged with graded doses of Bal or RT-SHIV, washed, and co-cultured with TZM.bl cells. Mean SFCs (6SD, triplicate
conditions) are shown from 1 of 4 experiments. (B) Carraguard-treated mature DCs were pulsed with Bal or RT-SHIV, washed, and co-cultured with
TZM.bl cells as in (A). The percent inhibition of infection (mean6SD, triplicate conditions) is shown for 1 of 4 experiments. A statistically significant
difference (p,0.05, two-tailed paired t-test) between the enhancement effects on Bal vs RT-SHIV infection is noted by the asterisk. (C) Mature DCs
pre-treated with Carraguard (Pre, open squares) were challenged with 3000 TCID50 of Bal or 4500 TCID50 of RT-SHIV, washed, and co-cultured with
TZM.bl cells. Alternatively, mature DCs were pulsed with virus, washed, added to TZM.bl cells and the graded doses of Carraguard added to the co-
cultures (Post, filled squares). The percent inhibition (mean6SD, triplicates) are shown from 1 of 4 experiments. A statistically significant difference
(p,0.01, two-tailed paired t-test) between the pre versus post Carraguard enhancement effects on Bal infection is noted by the asterisk.
doi:10.1371/journal.pone.0003162.g002
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inhibitory effects against R5 clinical HIV-1 isolates and an HIV-2
isolate [37]. Knowing that blockade of DC-driven infection can
require greater anti-viral drug potency to limit infection than is
required in other in vitro assays [61,62], we sought to determine the
efficacy of a high dose (500 mM) MIV-150/Carraguard combina-
tion formulation designated PC-817 in our DC systems and in vivo.
Unlike Carraguard, MIV-150 potently inhibited infection of
TZM.bl cells with HIVBal, RT-SHIV, and HIVMN at concentra-
tions below 3 nM (HIVBal IC50=2.94 nM61.20; RT-SHIV
IC50=0.99 nM60.10; HIVMN IC50=1.03 nM60.27; n=3 for
each virus) (Fig. 4A). We attempted synergy analysis using the
Chou-Talay algorithm as previously described [63], although both
HIVBal and RT-SHIV inhibition/enhancement curves did not
Figure 3. Carraguard inhibits infection in immature DCs coincident with DC maturation. (A) Immature DCs were pre-incubated with
graded doses of Carraguard, after which the DCs were challenged with Bal (down triangles) or HIV Denv pseudotyped with the VSVg envelope (Denv,
filled squares). Cells were harvested 5 d later and stained for (A) HIV capsid p24 protein (mAb KC-57-RD1) or (B) the surface maturation markers CD83
and CD86. (A) Percent inhibition (mean6SD, triplicates) of infection and (B) the MFIs (mean6SD of triplicates) of CD83 (black bar) and CD86 (grey
bar) expression (on the entire DC population) are shown for 1 of 4 replicate experiments. CD83 and CD86 up-regulation in response to increasing
doses of Carraguard correlate closely (r=0.99). (C) p24 expression is plotted against CD83, showing the correlation between lower CD83 levels and
HIV infection. Comparable results were obtained when comparing CD86 and p24 expression (data not shown).
doi:10.1371/journal.pone.0003162.g003
Figure 4. MIV-150 overrides the augmentation of DC-driven infection by Carraguard. (A) TZM.bl cells were pre-exposed to varying doses
of MIV-150, challenged with the indicated viruses. Mean percent inhibition (6SD, triplicates) is shown from 1 of 3 experiments. (B) Mature DCs pre-
treated with Carraguard (Carr Pre, open circles) or PC-817 (PC-817 Pre, open triangles; 33.3 nM MIV-150 per 2 mg/ml Carraguard) were pulsed with RT-
SHIV, washed, and co-cultured with TZM.bl cells. Alternatively, mature DCs were pulsed with virus, washed, added to TZM.bl cells and the graded
doses of Carraguard (Carr Post, filled circles) or PC-817 (PC-817 Post, filled triangles) added to the co-cultures. The concentrations indicated on the X
axis indicate the Carraguard concentrations for each formulation. The percents of inhibition (mean6SD, triplicates) are shown for 1 of 3 similar
experiments. (C) Mature DCs were treated with 2 mg/ml of Carraguard, pulsed with RT-SHIV, washed, and then cultured with TZM.bl cells in the
presence (Carr+MIV-150) or absence (Carr) of varying doses of MIV-150 (nM). Percent inhibition of infection (mean6SD, triplicates) are shown for 1 of
3 identical experiments.
doi:10.1371/journal.pone.0003162.g004
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and potency of the Carraguard curves were different to the typical
sigmoidal curve for MIV-150). Therefore, we restricted our studies
to the ability of MIV-150 to overcome the enhancement observed
in mature DC-driven RT-SHIV infection, the experimental
system that was most significantly enhanced by Carraguard. Pre-
treatment of DCs with either Carraguard or PC-817 and post-
treatment with Carraguard resulted in comparable levels of
enhancement of RT-SHIV infection, while addition of PC-817
to the DC/recipient mixtures (post-treatment) effectively inhibited
virus replication (Fig. 4B). Thus, the presence of MIV-150
overcame the enhancing effects of Carraguard. To more closely
examine the amounts of MIV-150 needed to overcome the
Carraguard enhancement of infection, titrated doses of MIV-150
were added to mature DC/recipient mixtures in the presence of
2 mg/ml Carraguard. Less than 1 nM of MIV-150 partially
reversed the enhancement by Carraguard, with complete
inhibition of virus replication being observed in the presence of
as little as 8 nM of MIV-150 (Fig. 4C, p,0.001).
Carraguard-based gels inhibit immunodeficiency virus
transmission in vivo
Concurrent with the in vitro research, in vivo studies were carried
out in order to compare Carraguard and PC-817 for their ability
to prevent vaginal RT-SHIV infection in macaques. Depo-
Provera-treated macaques had 3 ml of the indicated gels applied
vaginally and then varying doses of RT-SHIV were applied
30 min later. Doses of .3000 TCID50 of SIVmac239 (parental
strain of RT-SHIV) were shown to be relatively high based on
frequency of animal infections [64] and 300 TCID50 of
SHIV162P3 is commonly used in testing other microbicide
strategies [65,66]. Therefore, we compared a similar low end
dose of 10
3 TCID50 of RT-SHIV to two higher doses (10
4 and 10
5
TCID50), to more rigorously test the Carraguard-based gels. A
2.5% MC gel was used as the placebo to parallel the products used
in the Phase III clinical trial [8]. Vaginal challenge with RT-SHIV
infected animals in a dose-dependent manner, resulting in mean
peak viremias of approximately 7.8610
6, 2.8610
6, and 1.5610
6
SIV RNA copies/ml after challenge with 10
5,1 0
4, and 10
3
TCID50, respectively (66.7%, 83.3%, and 46% infection in the
MC-treated groups, Fig. 5). Analysis of the average area under the
curve of the viral loads in the MC control groups, confirmed the
correlation between the virus challenge dose and virus levels over
time (weeks 1 to 16, r
2=0.97).
Both Carraguard and PC-817 protected against vaginal RT-
SHIV infection and this was dependent on the dose of challenge
inoculum used (Fig. 5A). Neither gel protected against the 10
5
TCID50 dose of RT-SHIV, although the peak viral loads were
delayed1–2 weeksin3ofthe4 Carraguard-treatedanimalsand2 of
the 3 PC-817 treated animals compared to the infected MC-treated
animals (Fig. 5A, bottom row). However, Carraguard and PC-817
reduced RT-SHIV infection at both the 10
4 and 10
3 TCID50
challenge doses (Fig. 5A, middle and top rows, respectively). The 2
PC-817-treated animals infected after the 10
4 TCID50 challenge
showed typical plasma viremia peaking after 14 days, while the 1
Carraguard-treated animal infected after the 10
3 TCID50 challenge
showed a delayed peak viremia compared to the MC-treated
animals. Independent of the virus challenge dose and gel exposure,
all animals that became infected with RT-SHIV (repeated positive
samples) exhibited co-culture positivity and developed SIV-specific
Ab and cellular responses, as expected (Table 1). One Carraguard-
treated animal challenged with 10
4 TCID50 of RT-SHIV showed
one low positive reading of ,1000 copies/ml, but it was negative at
all other time points. This animal did not appear to have developed
adaptive SIV-specific responses that might have controlled infection
(Table 1), suggesting that either innate responses controlled
infection, that this was a false positive RNA result, or this was
evidence of an abortive infection [67]. This was supported by the
lack of the appearance of virus in the plasma after depletion of CD8
cells (for 2–3 weeks during which time increases in plasma virus
levels were observed in positive control animals) using the mAb cM-
T807 [68] (data not shown).
Due to the small sample size of each TCID50 challenge group,
statistical analyses were performed on the combined data from the
10
3 and 10
4 TCID50 groups where there was at least some
protective effect of the gels (Fig. 5B). Both Carraguard and PC-817
significantly inhibited infection (p,0.02 and p,0.03, respectively),
reducing the frequency of infection to at least 75% of that seen in
the MC-treated animals.
Activity of topically applied MIV-150 against RT-SHIV in
vivo
Since PC-817 did not appear to exhibit any additional activity
against vaginal RT-SHIV challenge above that seen with
Carraguard, we examined the ability of MIV-150 in MC to limit
vaginal spread. As predicted by the PC-817 data (Fig. 5), a single
dose of 500 mM of MIV-150 in MC given 30 min prior to vaginal
challenge with 10
3 or 10
4 TCID50 of RT-SHIV did not prevent
infection, although the peak viremia was delayed by 1–2 weeks in
all animals infected after challenge with 10
3 TCID50 and in one of
the animals receiving the higher inoculum (Fig. 6A). However,
repeated doses of 500 mM of MIV-150 (1.5 mM total) in MC
given 24 h before, 30 min before, and 24 h after challenge did
reduce RT-SHIV infection, delaying the peak viremia in 2 animals
(Fig. 6B). Compared to the MC control where 5 of 6 (,83%)
animals challenged with 10
4 TCID50 became infected (Fig. 5A),
only 3 of 7 (,43%) animals receiving the 3 doses of MIV-150 in
MC got infected and exhibited typical plasma viremias; MIV-150
reduced the frequency of normal infections by ,49%. Surpris-
ingly, 3 other animals were virus positive on repeated occasions
after challenge, but their peak viremias were 3–4 logs lower than
the placebo group, with virus ultimately becoming undetectable
after 1.5–3 months. Unlike typically infected animals, CD8
depletion of these 3 animals with the abnormally low infection
did not result in any rebound of plasma virus levels (Fig. 6C and
D). Just like the one uninfected animal, these animals did not
develop detectable SIV-specific Ab or T cell responses, which are
observed in most infected animals (Table 1). Thus, topically
applied MIV-150 can limit vaginal RT-SHIV infection.
Discussion
In vitro predictive indicators of potential microbicides are needed
prior to any animal efficacy testing. Although which tests can
predict in vivo efficacy is of much debate. The study herein,
presents an extreme example where most in vitro results were
discordant with those observed in vivo at several levels. For
instance, based on in vitro data alone, there is little supporting
evidence that Carraguard would be protective in vivo. Rather,
significant levels of enhancement were observed in vitro with our
challenge virus RT-SHIV when Carraguard levels were below
10 mg/ml in cell-free infections of cell lines and activated PBMCs
and also in cell-associated assays where mature DCs were used to
transfer to recipient cells. These enhancing effects were more
pronounced than has been reported previously [37], probably due
to the lower doses of gels employed herein, as well as the use of
mature DC assays and/or differing viral strains. The only
exception, in accord with the 10
3 and 10
4 TCID50 in vivo results,
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likely the result of indirect effects, as Carraguard also matured the
DCs, and DC maturation is associated with the reduced capacity
of viral production [16,69–72], even when DCs receive the
maturation stimulus after virus exposure [59,60].
Considerable evidence has demonstrated that polyanions like
Carraguard are significantly more effective against the positively
charged X4 viruses [24–29]. There have also been some reports of
polyanions enhancing infections on the basis of interactions with
the V1/V2 regions of envelope [26,27,73]. Herein, it is apparent
that the level of enhancement is also dependent on the R5 isolate
used, being most pronounced with RT-SHIV in the mature DC/
recipient co-cultures. The mechanism of in vitro enhancement
remains unclear and cannot be attributed to the two main
mechanisms needed for DC viral transfer: increased capture of
virus by the DCs or increased DC-T cell conjugate formation. In
Figure 5. Carraguard-based gels inhibit vaginal infection in macaques. Depo-Provera-treated animals were treated with 3 ml of MC,
Carraguard (Carr), or PC-817 30 min prior to challenge with 1 ml of or 10
3–10
5 TCID50 RT-SHIV. (A) Plasma viral loads were quantified by PCR and SIV
gag RNA copies per ml of plasma are shown for each animal over time. The numbers of animals in the respective groups are indicated in each panel.
Each symbol denotes a different animal (Table 1). (B) The frequencies (percentage of infected animals, mean6SEM) of infection in the MC,
Carraguard, and PC-817-treated groups challenged with 10
3 and 10
4 TCID50 are plotted. Carraguard (p,0.02) and PC-817 (p,0.03) significantly
reduced the frequency of immunodeficiency virus infection compared to the MC-treated placebo group.
doi:10.1371/journal.pone.0003162.g005
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Gel Virus Animal # Infection Culture
$ Ab IFNc CD4 cells/ml^
Pre 112 d post
MC 10
3 RT-SHIV FI80 ++ + + 1555 715
FI81 ++ + + 3204 1618
FI82 ++ + + 1679 1478
DE38
& 22 2 + 894 1283
GF15 22 2 2 556 565
GF16 22 2 2 1657 896
GJ43 ++ + + 1177 528
GJ51 ++ + + 1543 966
GK06 22 2 2 2346 1070
GK05 22 2 2 596 877
GF13 22 2 2 644 908
GJ29 22 2 2 883 823
GJ28 ++ + + 413 605
10
4 RT-SHIV GF23 ++ + 2 912 879
FI76 ++ 2 + 1498 1019
GF17 22 2 2 1016 1377
GF18 ++ + + 1941 2732
FI72 ++ + + 1501 616
FI74 ++ + + 1353 1178
10
5 RT-SHIV FI76 22 2 2 1029 1617
FI77 ++ 2 + 1061 ND
FI78 ++ + + 976 1135
Carraguard 10
3 RT-SHIV FI72 22 2 2 2381 3097
FI74 22 2 2 2652 3539
FI79 22 2 2 2457 2229
GJ38 ++ + 2 303 420
10
4 RT-SHIV GF13 22 2 2 1161 2346
GF14 2* 22 2 404 1064
GF15 22 2 2 663 882
GF16 22 2 2 1141 2175
FI72 22 2 2 1719 1973
FI74 22 2 2 2738 1981
FI79 22 2 2 1920 1306
10
5 RT-SHIV FI70 ++ + + 821 412
FI71 ++ 2 + 1042 1425
FI73 ++ + + 2984 1467
FI75 ++ + + 1712 805
Gel Virus Animal # Infection Culture
$ Ab IFNc CD4 cells/ml
Pre 112 d^ post
PC-817 10
3 RT-SHIV FI83 222 2 1337 1454
FI84 222 2 1806 3142
FI85 222 2 1531 1119
FI88 222 2 1107 1363
GJ34 222 2 956 1029
GJ41 222 2 981 972
10
4 RT-SHIV GF07 222 2 1744 2460
GF08 +++ + 965 1266
GF12 +++ + 1673 1895
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MIV-150 consistently was not only potent, but also very effective
against the virus isolates used with this study. Importantly, MIV-
150 also overcame the unsuspected enhancing effects of Carra-
guard in the mature DC/recipient mixtures. This supports the
initial report showing the potent effects of Carraguard and MIV-
150 in vitro against several R5 Clade C clinical isolates [37].
Based on these in vitro findings we would have predicted that
Carraguard would exhibit limited efficacy in preventing R5 RT-
SHIV infection in vivo, while the addition of MIV-150 to
Carraguard would render PC-817 considerably more effective.
This was, however, not the case and the in vivo data disagreed with
most of the in vitro data at three levels. Firstly, Carraguard did not
enhance infection in vivo. Secondly, Carraguard proved to be
effective against relatively high dose challenges (10
3 and 10
4
TCID50) of RT-SHIV. Thirdly, due to the efficiency of
Carraguard it was not possible to demonstrate any difference
between Carraguard and PC-817, with them both reducing
infection by at least 75% of that seen in MC placebo controls. This
is not the first observation of discrepancies between in vitro and in
vivo data. Several in vivo studies demonstrated that the level of the
compound needed to prevent infection in vivo is several orders of
magnitude higher than that seen in vitro [65,74–76]. Although in
all cases, investigators did not observe enhancement in vitro of their
test compound prior to in vivo testing. Thus, the study herein
presents a novel comparison where enhancement in vitro
contradicted effective inhibition in vivo.
Understanding which variable(s) were dominant in vivo, may aid
in the future design of in vitro assays to more consistently predict
the potential outcomes in animal models and ultimately in
humans. As in previous microbicide challenges in macaques
[4,65,66,76,77], there is an inordinately large amount of
compound being used topically relative to the test levels in vitro.
The in vivo dose of Carraguard (30 mg/ml) is at least 300 fold
higher than the maximum levels that can be used in vitro and more
than 3000 fold higher than the doses at which in vitro enhancement
was observed. This is largely due to the viscosity of the 30 mg/ml
solution, which is necessary for it to remain in place in vivo, but
which interferes with the in vitro assays. Complementing our
immature DC infection data, in vitro studies using tissue explants
Gel Virus Animal # Infection Culture
$ Ab IFNc CD4 cells/ml
Pre 112 d^ post
FI83 222 2 1920 933
FI84 222 2 2194 1428
FI85 222 2 935 1312
FI88 222 2 1297 1381
10
5 RT-SHIV FI86 +++ + 1018 1092
FI87 ++2 + 1429 568
FI89 +++ + 2092 ND
MIV-150 1X
% 10
3 RT-SHIV DK96 +++ + 1106 914
DE54 222 2 1241 1588
GF13 222 2 1244 889
GF15 +++ + 507 171
GF17 222 2 560 478
GJ31 222 2 403 383
GK01 +++ + 1744 1398
MIV-150 1X
% 10
4 RT-SHIV DE38 +++ + 1092 722
DE54 ++22 1549 467
MIV-150 3X
% 10
4 RT-SHIV GF21 +++ + 881 926
FI83 +++ + 1095 632
FI85 +++ 2 1088 1443
GF20 222 2 505 999
FI79 -/+
@ 22 2 1549 1007
FI84 -/+
@ 22 2 1327 1443
FI88 -/+
@ 22 2 738 784
^CD4 counts taken on day 84 for DE38, day 189 for FI76, FI78, FI70, FI71, FI73, and FI75, and day 196 for FI86 and FI87.
$Co-cultures of PBMCs with 1746CEM cells were scored as positive by microscopic examination of syncytia formation and in some instances verified by PCR for SIV gag.
&DE38 had two timepoints of positive IFNc responses at weeks 8 and 10 post challenge.
*GF14 - average 715 copies/ml on day 42 post challenge, but the animal remained below the level of detection at all other time points.
%500 mM of MIV-150 in MC administered once 30 min prior to challenge (1X) or 24 h before, 30 min before, and 30 min after virus challenge (3X).
@These animals exhibited low-level viremia but ultimately controlled infection to undetectable levels even after CD8 depletion.
Ab positivity was defined as having at least two positive OD values above baseline at 4 weeks post challenge and IFNc positivity was defined as having at least 50 SIV-
specific IFNc SFCs per 10
6 PBMCs on more than one time point post challenge.
ND, not determined.
doi:10.1371/journal.pone.0003162.t001
Table 1. cont.
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infection by 50%, even when it was used at only 3 mg/ml (10 fold
less than the recommended in vivo dose) [78]. It is likely that
Carraguard-based gels coat the epithelial surfaces providing a
primary barrier against HIV entering the tissues and reaching the
underlying leukocytes that would amplify infection. Only rare DC
processes extending to the epithelial surface or breaks in the tissue
caused by trauma or other infections would afford the gels direct
access to the underlying DCs. Since immature DCs dominate in
healthy epithelia, our data indicate that if Carraguard was to reach
the cells it would limit infection of the immature DCs under these
circumstances. As such, it is likely that the gel rarely encounters
mature DCs and T cells in which the enhancing effects were
observed in vitro. Importantly, there was no evidence of
enhancement of infection in macaques when the gels were applied
atraumatically 30 min prior to challenge. Having only ,50%
infection frequency in the control 10
3 TCID50 challenge group
would have allowed the detection of any significant adverse
enhancing effects of the gels if they had occurred. Analysis of
macaque vaginal swabs within the first days after a single
application of PC-817 (versus MC or nothing, 4 animals per
group) revealed no change in the levels of cytokines or chemokines
(Melissa Robbiani and Rachel Singer, unpublished observations).
This suggests a lack of immunomodulation in vivo as reported
recently in women [79]. There was no evidence of inflammation
or enhancement of infection in the recently completed Phase III
trial of Carraguard [8]. Furthermore, use of Carraguard 2–3 times
a week has been reported to be acceptable and safe, affording no
differences to the placebo-using couples [80] and daily use of
Carraguard for 7–14 d was found to be safe in HIV-infected men
and women [81].
Clearly, the outcome of the Phase III clinical trial is in
opposition to the in vivo macaque data presented within,
highlighting that challenges still lie ahead in the study design of
animal models predicting efficacy in clinical trials. For instance,
there are several variables that need to be considered in future
animal trials. Firstly, the placebo control gels need to match the
inherent rheological properties of the gel to be tested. The MC
placebo used herein did not exactly match rheological properties
of Carraguard, however MC was used in parallel in Phase III
clinical trials and therefore cannot explain the contrasting
observations in the animal studies presented herein. Secondly,
the means by which the virus is introduced is also of importance,
as the atraumatic application of cell-free virus in the macaque
model diverges from that occurring in heterosexual HIV
transmission in humans. Key variables in the latter situation are
Figure 6. In vivo activity of MIV-150-containing MC gels. Depo-Provera-treated animals were treated with (A) 3 ml of MC containing 500 mM
MIV-150 30 min prior to vaginal challenge with 10
3 or 10
4 TCID50 of RT-SHIV or (B) 3 ml of MC containing 500 mM MIV-150 24 h before, 30 min
before, and 24 h after vaginal challenge with 10
4 TCID50 of RT-SHIV. Plasma viral loads over time are shown for the indicated numbers of animals in
each group. One year after challenge the 3 animals with the low-level initial infection (now with undetectable virus) and two of the normally infected
animals were treated with the anti-CD8 mAb to deplete CD8 cells. (C) Effective depletion of CD8 cells was verified by flow cytometry and the CD8
cells per ml of blood are shown for each animal. (D) Analysis of the plasma virus loads before during and after CD8 depletion, revealed no rebound in
virus levels in the 3 animals with the unusual acute low-level infection. Each symbol denotes a different animal that are detailed in Table 1.
doi:10.1371/journal.pone.0003162.g006
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dry sex) introduction of virus in the form of either a cell-associated
or cell-free viral inocula in the presence of seminal fluid. The
presence of seminal fluid as an additional variable may actually
increase the effective viral inocula present, due to the presence of
semen-derived amyloid fibrils [82]. However, Carraguard-based
formulations show no limitations in activity in the presence of
seminal fluid in vitro [37].
Inclusion of an additional agent that broadens the activity of a
formulation (overcoming any potential limitations of the gel) is
highly advantageous. To this end, extremely low doses of MIV-
150 effectively inhibited infection and overcame any enhancing
effects of Carraguard in vitro, suggesting that this would increase
protection in vivo when comparing Carraguard versus PC-817.
Unfortunately, improved efficacy of PC-817 over Carraguard in
vivo could not be demonstrated, due to the potency of Carraguard
under these conditions, probably as a result of Carraguard’s strong
barrier effect. Supporting this, we observed that a single 500 mM
dose of MIV-150 in MC given 30 min prior to challenge was
unable to protect against vaginal infection. However, the in vivo
activity of topically applied MIV-150 was verified by the fact that
repeated doses of MIV-150 in MC reduced vaginal infection. This
possibly reflects the dosing and/or timing requirements for the
activity of MIV-150 to be evident. Since MIV-150 has both anti-
viral and virucidal activities, the need for higher doses could
indicate the need for more drug to be absorbed into the tissues
and/or that the virucidal effect is needed to limit spread, since
more MIV-150 was needed for virucidal effects in vitro [37].
Ongoing macaque studies are exploring how MIV-150 is acting in
vivo. These findings set the stage for future studies examining the
repeated (e.g., daily) application of gels that would allow women to
use them independent of coitus and macaque studies using
Carraguard-based gels (with and without MIV-150), are under-
way. Also, the topical activity of the NNRTI MIV-150 indicates
promise for alternative strategies employing anti-viral drug-
containing microbicide vaginal rings.
These studies provide direct evidence that Carraguard-based
gels can afford protection against immunodeficiency virus
infection when they are applied before atraumatic cell-free virus
exposure in the absence of seminal fluid. However, the lack of
protection within the recent Carraguard clinical trial emphasizes
how other variables in humans need to be addressed in future
study design using macaques in microbicide testing. These include
the viral inocula, the presence of seminal fluid, the challenge virus
used, single versus multiple virus applications and inclusion of
mechanical disruption that mimics coitus. Unfortunately, not all
variables can be addressed in animal models. For instance,
additional post-hoc survival analyses in the Phase III clinical trial
of Carraguard based on behavior, other risk factors, and
adherence levels revealed that HIV incidence continued to be
lower in the Carraguard group among the women who used the
gel during 100% of sex acts, although this also did not reach
statistical significance (Robin Maguire, personal communication).
Importantly, adherence to using the gel was a significant problem
and it is not clear when the supposedly compliant women actually
used the gel relative to sexual intercourse. It is quite likely that the
window of opportunity for a gel to be effective when used as a
single application will be narrower than that for repeated (e.g.,
daily) use, thereby further undermining the efficacy of a single dose
product. In summary, the data herein demonstrate the efficacy of
Carraguard-based gels at preventing vaginal infection in a
controlled environment. Moreover, we provide the first evidence
that topically applied MIV-150 can restrict vaginal RT-SHIV
infection. Together, this sets the stage for future research on anti-
HIV strategies (repeated gel applications, or long term drug
release from vaginal rings) that would afford greater activity
against HIV infection.
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